The content on this site is intended for healthcare professionals only
Dr Hongnan Mo speaks to ecancer about the efficacy and safety of toripalimab and metronomic chemotherapy in HER2-negative metastatic breast cancer.
This study was a multicenter phase II trial based on a Bayesian adaptive randomised design.
This is the first clinical trial of metronomic chemotherapy combined with PD-1 blockade compared with the efficacy of combined conventional chemotherapy and immune checkpoint blockade.
The results of this study suggest promising clinical efficacy and evidence of cooperativity between metronomic VEX chemotherapy and PD-1 blockade.
Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC
One-year mortality in older adults with breast cancer: prediction using different geriatric tools
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC
ASCO 2023: Breast cancer research highlights
The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer
